Medacta international sa private company information – bloomberg hip dysplasia surgery

Medacta International SA engages in the production and sale of medical products for the orthopedic industry. It offers hip products, including stems, cups, heads, and bone cement; knee products, including patient matched cutting blocks, knees, other implants, and navigation systems; spine products, including unconstrained screw technology and cervical intervertebral body fusion devices; and instruments, including cleaning products, decontamination and sterilization products, woodpecker motors and accessories, chana reamer handles, and instruments trays. The company also offers support to healthcare professionals in the field of research and education, including round table discussions, natio…

Medacta International SA engages in the production and sale of medical products for the orthopedic industry.


It offers hip products, including stems, cups, heads, and bone cement; knee products, including patient matched cutting blocks, knees, other implants, and navigation systems; spine products, including unconstrained screw technology and cervical intervertebral body fusion devices; and instruments, including cleaning products, decontamination and sterilization products, woodpecker motors and accessories, chana reamer handles, and instruments trays. The company also offers support to healthcare professionals in the field of research and education, including round table discussions, national and international reference center visits, cadaver wet labs, product club meetings, live surgeries, and difficult case evaluation. Medacta International SA was formerly known as Bieffe Biochimici Firenze. The company was founded in 1958 and is based in Castel San Pietro, Switzerland with locations in Buenos Aires, Argentina; Dorf, Austria; Sydney, Australia; Nivelles, Belgium; Rio de Janeiro, Brazil; Kitchener, Canada; Göppingen, Germany; Barcelona, Spain; Villeneuve la Garenne, France; Leicestershire, United Kingdom; Athens, Greece; Jakarta, Indonesia; Milano, Italy; Tokyo, Japan; Ankara, Turkey; Camarillo, California; and Johannesburg, South Africa.

Medacta® International launched its new MOTO™ Medial Partial Knee System, Medacta Shoulder System and a third offset option for its MasterLoc™ Hip System at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held March 6-10 in New Orleans, Louisiana. Medacta’s MOTO Medial Partial Knee System is a compartment-specific, fixed-bearing solution for partial knee replacement, or unicompartmental knee arthroplasty (UKA), in which only a portion of the knee is resurfaced. Partial knee replacements are rapidly becoming a common choice for orthopedic surgeons seeking to offer patients the option of pain relief in the outpatient setting. With patient demand on the rise, Medacta designed the MOTO System and detailed education platform to simplify common procedural challenges and make partial knee cases easier to perform in an outpatient setting. The MOTO implants are designed for each specific compartment using an anthropometric database of more than 45,000 CT and MRI knee scans to optimize anatomic coverage, contours, size range and precise fit. Perhaps the most distinguishing feature of MOTO is the instrumentation that allows for precise bone resections to balance knee flexion-extension gap mismatch, while maintaining slight alignment under-correction. In keeping with its commitment to surgeon education and training, Medacta created a unique education program around the MOTO Partial Knee that provides top-level medical education and continuous support to ensure surgeons transitioning to using the implant have adequate support and are able to deliver the best possible outcomes to their patients. The Medacta Shoulder System is a modular solution designed to address the unique challenges around complex shoulder arthritis. Developed by an international team of expert surgeons, the platform offers both Anatomic and Reverse Shoulders to deliver the modularity and compatibility demanded by today’s marketplace. Its unparalleled implant selection allows for an anatomic fit for a wide range of pathologies, with other options including wide-ranging sizes, adjustable offsets and other innovative configurations. With the addition of the LAT PLUS, Medacta’s MasterLoc Hip System is the only flat-tapered wedge stem for total hip replacement with a unique progressive triple offset, giving surgeons more options to better suit their patients’ needs without impacting leg length. Adding to the MasterLoc’s existing standard offset (STD) and lateralized version (LAT), which adds an extra six millimeters of femoral offset to the STD, the LAT PLUS offers another five millimeters of offset to help surgeons enhance component stability. The MasterLoc Hip System was introduced in November 2016 as another addition to Medacta’s cementless implant portfolio. The MasterLoc features Medacta’s Mectagrip plasma-sprayed titanium coating, designed to enhance initial fixation with its high coefficient of friction and the potential long-term stability inherent to titanium plasma-sprayed devices.

Medacta International announced the introduction of the MiniMAX Hip System into its U.S. product portfolio. The MiniMAX is an anatomical cementless stem that is engineered to provide enhanced fit and fill in the metaphyseal femur by following the natural shape of the femoral canal with a unique curved design, ideal for both minimally invasive anterior and posterior hip replacement procedures. The launch follows the successful first stateside surgery utilizing the stem, which was performed by David Scott, M.D., of Spokane, Washington, on September 12. The MiniMAX Hip Stem aims to reduce risk and postoperative pain for patients while making it easier for surgeons to introduce it into the femur. The MiniMAX’s lateral flare design minimizes fracture, and its nine degrees of neck anteversion can provide more joint stability and reduce the risk of dislocation. The short, thin tip with five degrees of curvature lowers the risk of thigh pain caused by distal interference. The implant’s proximal titanium plasma spray and hydroxyapatite coating provide enhanced proximal fixation. First introduced in Europe in 2007, the MiniMAX Hip Stem is associated with proven clinical results, obtaining a survival rate at 5 years of 97.5% considering revision for any reason and 100% considering aseptic loosening as endpoint, according to internal Medacta research.